{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:42:20Z","timestamp":1792791740996,"version":"4.5.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105655","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:50:37Z","timestamp":1792597837000},"page":"105655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neurofibromin in breast cancer"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-8733","authenticated-orcid":false,"given":"Armen","family":"Parsyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2026.105655_bib1","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1158\/1078-0432.CCR-20-4048","article-title":"Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer","volume":"27","author":"Akcakanat","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105655_bib2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/jmg.28.11.752","article-title":"Watson syndrome: is it a subtype of type 1 neurofibromatosis?","volume":"28","author":"Allanson","year":"1991","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib3","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049362","article-title":"RAS and beyond: the many faces of the neurofibromatosis type 1 protein","volume":"15","author":"Anastasaki","year":"2022","journal-title":"Dis. Model. Mech."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105655_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/10600280211046298","article-title":"A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas","volume":"56","author":"Anderson","year":"2022","journal-title":"Ann. Pharmacother."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105655_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41588-019-0507-7","article-title":"The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies","volume":"51","author":"Angus","year":"2019","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105655_bib6","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/j.1600-0625.2009.01017.x","article-title":"Decreased expression of neurofibromin contributes to epithelial-mesenchymal transition in neurofibromatosis type 1","volume":"19","author":"Arima","year":"2010","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.critrevonc.2026.105655_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1375441","article-title":"Nf1 deficiency modulates the stromal environment in the pretumorigenic rat mammary gland","volume":"12","author":"Arumugam","year":"2024","journal-title":"Front. Cell. Dev. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib8","article-title":"N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kalpha inhibition in breast cancer","volume":"4","author":"Auf der Maur","year":"2023","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s42003-023-04815-0","article-title":"The therapeutic potential of neurofibromin signaling pathways and binding partners","volume":"6","author":"Baez-Flores","year":"2023","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","article-title":"The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins","volume":"63","author":"Ballester","year":"1990","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105655_bib11","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1535-7163.MCT-15-0243","article-title":"MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model","volume":"14","author":"Bartholomeusz","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"6371","key":"10.1016\/j.critrevonc.2026.105655_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/356713a0","article-title":"Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients","volume":"356","author":"Basu","year":"1992","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib13","article-title":"Adjuvant Radiation Therapy in Breast Cancer Patients With Neurofibromatosis Type 1: Safety and Long-Term Outcomes","volume":"11","author":"Benmatallah","year":"2026","journal-title":"Adv. Radiat. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105655_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112365","article-title":"Neurofibromin Structure, Functions and Regulation","volume":"9","author":"Bergoug","year":"2020","journal-title":"Cells"},{"issue":"7757","key":"10.1016\/j.critrevonc.2026.105655_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic characterization of metastatic breast cancers","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105655_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2026.102934","article-title":"Spatial proteomic profiling reveals an association between NF1-Ras\/Raf\/MEK signaling and immune cell infiltration in locally advanced triple-negative breast cancer","volume":"72","author":"Bhat","year":"2026","journal-title":"Transl. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105655_bib17","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.262343","article-title":"Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss","volume":"137","author":"Bouley","year":"2024","journal-title":"J. Cell. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib18","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/09647041003642885","article-title":"A history of von Recklinghausen's NF1","volume":"19","author":"Brosius","year":"2010","journal-title":"J. Hist. Neurosci."},{"issue":"801","key":"10.1016\/j.critrevonc.2026.105655_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk7786","article-title":"Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers","volume":"17","author":"Cai","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"7418","key":"10.1016\/j.critrevonc.2026.105655_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0092-8674(90)90253-B","article-title":"A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations","volume":"62","author":"Cawthon","year":"1990","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105655_bib23","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.molcel.2022.03.011","article-title":"Structural basis of activation of the tumor suppressor protein neurofibromin","volume":"82","author":"Chaker-Margot","year":"2022","journal-title":"Mol. Cell."},{"issue":"10496","key":"10.1016\/j.critrevonc.2026.105655_bib24","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study","volume":"405","author":"Chen","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105655_bib25","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/1878-0261.13416","article-title":"ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes","volume":"17","author":"Chen","year":"2023","journal-title":"Mol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105655_bib26","doi-asserted-by":"crossref","first-page":"E2215","DOI":"10.1073\/pnas.1701512114","article-title":"Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification","volume":"114","author":"Chen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib27","article-title":"Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling","volume":"8","author":"Chen","year":"2020","journal-title":"Mol. Genet. Genom. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105655_bib28","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1158\/0008-5472.CAN-12-1728","article-title":"Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms","volume":"72","author":"Choi","year":"2012","journal-title":"Cancer Res."},{"issue":"7403","key":"10.1016\/j.critrevonc.2026.105655_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/sj.embor.7400602","article-title":"A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein","volume":"7","author":"D'Angelo","year":"2006","journal-title":"EMBO Rep."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105655_bib31","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J. Cancer"},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105655_bib32","doi-asserted-by":"crossref","first-page":"8949","DOI":"10.1523\/JNEUROSCI.23-26-08949.2003","article-title":"The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes","volume":"23","author":"Dasgupta","year":"2003","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105655_bib33","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1086\/498454","article-title":"NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome","volume":"77","author":"De Luca","year":"2005","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","article-title":"Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis","volume":"69","author":"DeClue","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105655_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104618","article-title":"Subtype distribution, clinical presentation, and molecular spectrum of neurofibromatosis type 1-associated breast cancer","volume":"84","author":"Di Giosaffatte","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105655_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-018-0080-8","article-title":"NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer","volume":"4","author":"Dischinger","year":"2018","journal-title":"NPJ Breast Cancer"},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105655_bib37","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.1073\/pnas.1607298113","article-title":"The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation","volume":"113","author":"Dunzendorfer-Matt","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14030510","article-title":"Age-Associated Genetic Variations in Breast Cancer: Somatic Mutations and Co-Mutations","volume":"14","author":"Ekinci","year":"2026","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib40","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41436-019-0651-6","article-title":"Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study","volume":"22","author":"Evans","year":"2020","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/jmedgenet-2018-105599","article-title":"Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation","volume":"56","author":"Frayling","year":"2019","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","article-title":"Epidemiology of neurofibromatosis type 1","volume":"89","author":"Friedman","year":"1999","journal-title":"Am. J. Med. Genet."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105655_bib43","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/13543784.2023.2263836","article-title":"NF1 alterations in cancers: therapeutic implications in precision medicine","volume":"32","author":"Giraud","year":"2023","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4103\/idoj.idoj_569_23","article-title":"Selumetinib-A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis","volume":"15","author":"Gorai","year":"2024","journal-title":"Indian. Dermatol. Online J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib45","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1038\/s41467-018-05914-x","article-title":"The prognostic effects of somatic mutations in ER-positive breast cancer","volume":"9","author":"Griffith","year":"2018","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105655_bib46","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5313","key":"10.1016\/j.critrevonc.2026.105655_bib47","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.276.5313.795","article-title":"Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides","volume":"276","author":"Guo","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105655_bib48","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105655_bib49","doi-asserted-by":"crossref","first-page":"9658","DOI":"10.1073\/pnas.88.21.9658","article-title":"Identification of the neurofibromatosis type 1 gene product","volume":"88","author":"Gutmann","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2026.105655_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.canlet.2006.01.018","article-title":"Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors)","volume":"245","author":"Hirokawa","year":"2007","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4161\/cbt.5.3.2404","article-title":"Sichuan pepper extracts block the PAK1\/cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice","volume":"5","author":"Hirokawa","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105655_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101876","article-title":"NF1 deficiency drives metabolic reprogramming in ER+ breast cancer","volume":"80","author":"House","year":"2024","journal-title":"Mol. Metab."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105655_bib53","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40265-025-02190-0","article-title":"Mirdametinib: First Approval","volume":"85","author":"Hoy","year":"2025","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105655_bib54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s10637-017-0459-7","article-title":"A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors","volume":"35","author":"Infante","year":"2017","journal-title":"Invest. New. Drugs"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105655_bib55","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7471","key":"10.1016\/j.critrevonc.2026.105655_bib56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105655_bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-018-0089-z","article-title":"Molecular determinants of post-mastectomy breast cancer recurrence","volume":"4","author":"Keene","year":"2018","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105655_bib58","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2767-9764.CRC-23-0044","article-title":"Proteogenomic Approaches for the Identification of NF1\/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment","volume":"3","author":"Kim","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 gene in tumor syndromes and melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Lab. Invest."},{"issue":"37","key":"10.1016\/j.critrevonc.2026.105655_bib60","doi-asserted-by":"crossref","first-page":"59932","DOI":"10.18632\/oncotarget.11000","article-title":"MicroRNA 10b promotes abnormal expression of the proto-oncogene c-Jun in metastatic breast cancer cells","volume":"7","author":"Knirsh","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.23929","article-title":"Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1","volume":"41","author":"Koczkowska","year":"2020","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.critrevonc.2026.105655_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1897-4287-12-5","article-title":"Neurofibromatosis type I with breast cancer: not only for women!","volume":"12","author":"Lakshmaiah","year":"2014","journal-title":"Hered. Cancer Clin. Pract."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib64","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1038\/s41467-020-19342-3","article-title":"Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing","volume":"11","author":"Lang","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105655_bib65","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/59.9.759","article-title":"Loss of neurofibromin is associated with activation of RAS\/MAPK and PI3-K\/AKT signaling in a neurofibromatosis 1 astrocytoma","volume":"59","author":"Lau","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.critrevonc.2026.105655_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104545","article-title":"Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer","volume":"83","author":"Li","year":"2025","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib67","article-title":"Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer","volume":"11","author":"Lim","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105655_bib68","article-title":"Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization","volume":"5","author":"Liu","year":"2025","journal-title":"Cell. Genom."},{"key":"10.1016\/j.critrevonc.2026.105655_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105828","article-title":"A bedside-to-bench translational analysis of NF1 alterations and CDK4\/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer","volume":"118","author":"Lloyd","year":"2025","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105655_bib70","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41594-021-00687-2","article-title":"The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1","volume":"28","author":"Lupton","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105655_bib71","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/ajmg.a.35550","article-title":"Increased risk of breast cancer in women with NF1","volume":"158A","author":"Madanikia","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105655_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/jscr\/rjw138","article-title":"Neurofibromatosis type 1 and male breast cancer: emerging risk factor?","volume":"2017","author":"Mann","year":"2017","journal-title":"J. Surg. Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105655_bib73","article-title":"Characterizing neurofibromin 1-altered breast cancer through genomic, functional, and clinical analyses","author":"Mao","year":"2025","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib74","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0888-7543(91)90017-9","article-title":"cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product","volume":"11","author":"Marchuk","year":"1991","journal-title":"Genomics"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","article-title":"The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21","volume":"63","author":"Martin","year":"1990","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib76","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/path.5184","article-title":"Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications","volume":"247","author":"McCart Reed","year":"2019","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105655_bib77","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cam4.551","article-title":"Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1","volume":"4","author":"McPherson","year":"2015","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105655_bib78","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1073\/pnas.1018872108","article-title":"Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen","volume":"109","author":"Mendes-Pereira","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105655_bib79","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/1535-7163.MCT-13-0482","article-title":"Concordance of genomic alterations between primary and recurrent breast cancer","volume":"13","author":"Meric-Bernstam","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105655_bib80","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105655_bib81","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/1535-7163.MCT-24-0593","article-title":"Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers","volume":"24","author":"Mughees","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105655_bib82","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s11912-024-01527-4","article-title":"Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors","volume":"26","author":"Na","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib83","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-3835(01)00648-6","article-title":"Human breast cancer MDA-MB-231 cells fail to express the neurofibromin protein, lack its type I mRNA isoform and show accumulation of P-MAPK and activated Ras","volume":"172","author":"Ogata","year":"2001","journal-title":"Cancer Lett."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105655_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914862","article-title":"RNA-Based Strategies for Cancer Therapy: In Silico Design and Evaluation of ASOs for Targeted Exon Skipping","volume":"24","author":"Pacelli","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib85","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","article-title":"Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance","volume":"26","author":"Pearson","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","article-title":"The NF1 somatic mutational landscape in sporadic human cancers","volume":"11","author":"Philpott","year":"2017","journal-title":"Hum. Genom."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-024-07551-z","article-title":"Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795\/uprosertib in patients with metastatic triple negative breast cancer","volume":"210","author":"Prasath","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105655_bib89","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jmg.2007.049346","article-title":"Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening","volume":"44","author":"Sharif","year":"2007","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib90","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1038\/s41467-021-27093-y","article-title":"HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdy497","article-title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","volume":"30","author":"Sokol","year":"2019","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105655_bib92","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1101\/gad.190876.112","article-title":"A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1","volume":"26","author":"Stowe","year":"2012","journal-title":"Genes. Dev."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib93","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/pgs-2018-0161","article-title":"NF1 regulates apoptosis in ovarian cancer cells by targeting MCL1 via miR-142-5p","volume":"20","author":"Su","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105655_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262010072","article-title":"Neurofibromin Encoded by the Neurofibromatosis Type 1 (NF1) Gene Promotes the Membrane Translocation of SPRED2, Thereby Inhibiting the ERK Pathway in Breast Cancer Cells","volume":"26","author":"Su Pwint","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105655_bib95","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13053-019-0110-z","article-title":"Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature","volume":"17","author":"Suarez-Kelly","year":"2019","journal-title":"Hered. Cancer Clin. Pract."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BD-140387","article-title":"Neurofibromatosis with male breast cancer--risk factor or co-incidence? Report of two rare cases","volume":"35","author":"Tandon","year":"2015","journal-title":"Breast Dis."},{"key":"10.1016\/j.critrevonc.2026.105655_bib97","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12935-020-01570-8","article-title":"Advancement in research and therapy of NF1 mutant malignant tumors","volume":"20","author":"Tao","year":"2020","journal-title":"Cancer Cell. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib98","first-page":"90","article-title":"Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a family with features of Watson syndrome and Noonan syndrome","volume":"53","author":"Tassabehji","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2026.105655_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104717","article-title":"Breast cancer risk in women with neurofibromatosis type 1: a register-based cohort study from Denmark and Sweden","volume":"86","author":"Tettamanti","year":"2026","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105655_bib100","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","article-title":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","volume":"33","author":"Torres-Masjoan","year":"2025","journal-title":"Mol. Ther."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105655_bib101","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib102","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","article-title":"Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus","volume":"62","author":"Viskochil","year":"1990","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib103","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41698-025-01045-x","article-title":"Genomic characterization of tumor mutational burden-high breast carcinomas","volume":"9","author":"Vougiouklakis","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib104","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1534\/genetics.112.142802","article-title":"Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver","volume":"192","author":"Wallace","year":"2012","journal-title":"Genetics"},{"issue":"4965","key":"10.1016\/j.critrevonc.2026.105655_bib105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.2134734","article-title":"Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients","volume":"249","author":"Wallace","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105655_bib106","first-page":"721","article-title":"Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"182","key":"10.1016\/j.critrevonc.2026.105655_bib107","doi-asserted-by":"crossref","first-page":"527","DOI":"10.24976\/Discov.Med.202436182.49","article-title":"Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K\/AKT\/mTOR","volume":"36","author":"Wang","year":"2024","journal-title":"Discov. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib108","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jmb.2006.11.055","article-title":"The sec14 homology module of neurofibromin binds cellular glycerophospholipids: mass spectrometry and structure of a lipid complex","volume":"366","author":"Welti","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib109","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/humu.21405","article-title":"Structural and biochemical consequences of NF1 associated nontruncating mutations in the Sec14-PH module of neurofibromin","volume":"32","author":"Welti","year":"2011","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib110","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(90)90149-9","article-title":"The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae","volume":"63","author":"Xu","year":"1990","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105655_bib111","article-title":"Exploiting metabolic vulnerabilities in breast cancers with NF1 loss","volume":"4","author":"Yap","year":"2023","journal-title":"Cell. Rep. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib112","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-4851-6","article-title":"Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype","volume":"171","author":"Yap","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105655_bib113","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","article-title":"Genomic Evolution of Breast Cancer Metastasis and Relapse","volume":"32","author":"Yates","year":"2017","journal-title":"Cancer Cell."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105655_bib114","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208960120","article-title":"Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization","volume":"120","author":"Young","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib115","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1038\/s41467-024-50262-8","article-title":"Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression","volume":"15","author":"Zahraeifard","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105655_bib116","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ejca.2015.03.016","article-title":"Fulvestrant with or without selumetinib, a MEK 1\/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21\/08","volume":"51","author":"Zaman","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105655_bib117","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.3892\/mmr.2016.5760","article-title":"Molecular screening strategies for NF1-like syndromes with cafe-au-lait macules (Review)","volume":"14","author":"Zhang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105655_bib118","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1427","article-title":"IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner","volume":"13","author":"Zhang","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105655_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218636","article-title":"NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis","volume":"655","author":"Zhao","year":"2026","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccell.2020.02.003","article-title":"Neurofibromin Is an Estrogen Receptor-alpha Transcriptional Co-repressor in Breast Cancer","volume":"37","author":"Zheng","year":"2020","journal-title":"Cancer Cell."},{"issue":"813","key":"10.1016\/j.critrevonc.2026.105655_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq5492","article-title":"NF1-depleted ER(+) breast cancers are differentially sensitive to CDK4\/6 inhibitors","volume":"17","author":"Zheng","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105655_bib122","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/s12885-016-2773-4","article-title":"Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells","volume":"16","author":"Zhou","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105655_bib123","first-page":"1797","article-title":"MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1","volume":"19","author":"Zhu","year":"2020","journal-title":"Exp. Ther. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:29:35Z","timestamp":1792790975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":123,"alternative-id":["S1040842826005421"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105655","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurofibromin in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105655"}}